Abstract
Biological and clinical observations suggest that initial marked reduction of resistant clones may be critical in any attempt to improve long-term results in advanced neuroblastoma (NB). The aim of this pilot study is to determine short-term toxicity and efficacy of a new therapeutic model based on the simultaneous use of multiple drug chemotherapy and specific irradiation using 131-I-MIBG. The study population consisted of 21 patients, from 1 to 8 years of age with good 131-I-MIBG uptake. 16 extensively pre-treated patients with refractory or relapsed disease were divided into 2 groups. In Group 1 (9 patients) the basic chemotherapy regimen consisted in cisplatin at the dose of 20 mg/m2i.v. per day infused over 2 h, for 4 consecutive days; on day 4 Cy 2 g/m2i.v. was administered over 2 h followed by Mesna. Group 2 (7 patients) was treated with basic chemotherapeutic regimen plus VP16 and Vincristine. VP16 at the dose of 50 mg/m2i.v. per day was administered as a 24 h infusion on days 1–3; Vincristine 1.5 mg/m2i.v. was administered on days 1 and 6. On day 10 a single dose of 131-I-MIBG (200 mCi) with a high specific activity (>1.1 GBq/mg) was administered to both Groups by i.v. infusion over 4–6 hours. A further 5 patients were treated at diagnosis: 2 with the same regimen as Group 1 and 3 with the same as Group 2. The severity of toxicity was graded according to World Health Organization (WHO) criteria. Assessment of tumour response was monitored 4–6 weeks after the beginning of combined therapy (CO-TH). Response was defined according to INSS (International Neuroblastoma Staging System) criteria. No extra-medullary toxicity was observed in any patient. Haematological toxicity was the only toxicity observed and seemed mainly related to chemotherapy. Myelosuppression was mild in the 5 patients treated at diagnosis. No serious infections or significant bleeding problems were observed. In the 16 resistant patients, 12 PR, 1 mixed response and 3 SD were obtained. In the 5 patients treated at diagnosis 2 PR, 1 CR and 2 VGPR were observed. No alteration in 131-I-MIBG uptake was observed after the chemotherapy preceding radio-metabolic treatment. The therapeutic results of this pilot regimen of CO-TH resulted in a high percentage of major response after only a single course in both resistant patients and patients treated at diagnosis. Because of the minimal toxicity observed in patients studied at diagnosis so far, there is room for gradual intensification of the treatment. It is to be hoped that this suggested novel approach may represent an important route of investigation to improve final outcome in patients with advanced NB. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Armour A, Cunnigham SH, Gaze MN, Wheldon TE and Mairs RJ (1997) The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 75: 470–476
Beierwaltes WH (1987) Treatment of neuroblastoma with 131-I-MIBG: dosimetric problems and perspective. Med Ped Oncol 15: 188–191
Brodeur GM, Pritchard J and Berthold F (1993) Revision of the International Criteria for Neuroblastoma diagnosis, staging and response to treatment. J Clin Onc 11: 1466–1477
DeKraker J, Hoefnagel CA and Caron H (1995) First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 31A: 600–602
Frappaz D, Michon J and Hartmann O (1992) Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 10: 1592–1601
Geatti O, Shapiro B and Sisson JC (1985) Iodine-131 metaiodobenzylguanidine for the location of neuroblastoma: Preliminary experience in ten cases. J Nucl Med 26: 736–742
Iavarone A, Lasorella A and Servidei T (1993) Uptake and storage of m-iodobenzylguanidine by neuroblastoma cells results from indipendent uptake and storage mechanism. Cancer Res 51: 4342–4346
Lashford LS, Lewis IJ and Fielding SL (1992) Phase I/II study of iodine 131-I-Metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol 10: 1889–1896
Mastrangelo R (1987) Editorial: The treatment of neuroblastoma with 131I-MIBG. Med Ped Oncol 15: 157–158
Mastrangelo R and Voute PA (1991) Session on the treatment of neuroblastoma with radioiodinated metaiodobenzylguanidine. Chairmen’s Report. J Nucl Biol Med 35: 260–262
Mastrangelo R, Troncone L, Lasorella A, Riccardi R, Montemaggi P and Rufini V (1989) 131I-MIBG in the treatment of neuroblastoma at diagnosis. J Ped Hematol Oncol 11: 28–31
Mastrangelo R, Lasorella A and Iavarone A (1993) Critical Observation on neuroblastoma treatment with 131-I-metadiodobenzylguanidine at diagnosis. Med Ped Oncol 21: 411–415
Mastrangelo R, Tornesello A and Riccardi R (1995) A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]metaiodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 31A(4), 4. 606–611
Mastrangelo R, Tornesello A and Lasorella A (1997) Optimal use of 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 31(1–2): 153–158
Matthay KK, Villablanca JG, Seeger RC and Stram DO (1996) Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoid acid. N Engl J Med 341: 1165–1173
Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK and Price D (1998) Phase I dose escalation of 131I-Metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Onc 16: 229–236
Meco D, Lasorella A, Riccardi A, Rumi C, Riccardi R and Mastrangelo R (1997) Chemotherapy and MIBG uptake in neuroblastoma cell lines. SIOP XXIX Meeting, Istanbul. Med Ped Oncol 29: 374
Millar JL and Hudspith BN (1976) Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with γ-irradiation. Cancer Treat Rep 60: 409–414
Millar JL, Blacker NM and Hudspith BN (1971) Enhanced post-irradiation recovery of the hematopoietic system in animals pretreated with a variety of cytotoxic agents. Cell Tissue Kinet 11: 543–553
Philip T, Ghalie R and Pinkerton R (1987) A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d’Oncologie Pédiatrique. J Clin Oncol 5: 941–950
Pinkerton R, Zucher JM and Hartmann O (1990) Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma (ENSG 3C induction regimen). Br J Cancer 62: 319–323
Riccardi R Unpublished observations,
Simone JV (1984) The treatment of neuroblastoma. J Clin Oncol 2(7): 717–718
Wieland DM, Wu J-L and Brown LE (1980) Radiolabeled adrenergic neuron-labeling agents: Adrenomedullary imaging with131Iliodobenzylguanidine. J Nucl Med 21: 349–353
World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment, Geneva, Switzerland, World Health Organization
Yan R, Peters LJ and Travis EL (1991) Cyclophosphamide 24 hours before or after total body irradiation: effect on lung and bone marrow. Radioth Oncol 21: 149–156
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mastrangelo, S., Tornesello, A., Diociaiuti, L. et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 84, 460–464 (2001). https://doi.org/10.1054/bjoc.2000.1645
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1645
Keywords
This article is cited by
-
Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma
European Journal of Nuclear Medicine and Molecular Imaging (2019)
-
Current Consensus on I-131 MIBG Therapy
Nuclear Medicine and Molecular Imaging (2018)
-
Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors
Annals of Nuclear Medicine (2015)